Depression
Conditions
Keywords
cytokine, depression, escitalopram
Brief summary
The association of cytokines with escitalopram has not been investigated in patients with major depressive disorder (MDD). Hence, the investigators will examine this association.
Detailed description
In addition to serotonin, inflammatory process has been suggested in the development of major depressive disorder (MDD) and in its associated treatment. Escitalopram is an antidepressant that has been widely used in patients with MDD because of the promising results. The association of cytokines with escitalopram has not been investigated in patients with MDD. Hence, the investigators will examine this association.
Interventions
DRUGEscitalopram
escitalopram 10 mg/d to 20 mg/d
Sponsors
Beitou Armed Forces Hospital, Taipei, Taiwan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. DSM-IV-defined Major depressive disorder, single episode 2. Age 20-65 3. Drug-naive 4. Hamilton Depression Rating Scale exceeding 14 scores
Exclusion criteria
1. Major medical disorders 2. Substance use 3. Pregnant 4. Allergy to escitalopram
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The changes in cytokines | Week 0, Week 4 | Hamilton Depression Rating Scale, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP-1β, TNF-α |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The changes in Hamilton Depression Rating Scale | week 0, week 4 | Hamilton Depression Rating Scale, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP-1β, TNF-α |
Countries
Taiwan
Contacts
Primary ContactPei-Shen Ho, M.D.
Outcome results
None listed